Research

This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups (NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply.

This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator­ initiated Research Project Grant (R01) or equivalent application.

Only New Investigators who fit the criteria in this section are eligible to apply to this FOA.

New Investigators whose proposed research addresses topics of relevance to the NIDCR mission are eligible and encouraged to apply. A New Investigator is one who has not previously competed successfully for substantial, independent R01 or R01-equivalent funding from NIH. When Multiple PDs/PIs are proposed, all PDs/PIs must meet the definition of New Investigator and the eligibility criteria as defined below. Current or past recipients of the NIDCR Small Grant for New Investigators (R03) grant are eligible to apply for a second NIDCR Small Grant for New Investigators (R03), provided they are still New Investigators. New Investigator status should be valid at the time of award.

Specifically, NIDCR is excluding from consideration individuals who have received:

NIH Exploratory/Developmental Research Grant (R21) support from any NIH Institute or Center, or
More than one Small Grant for New Investigators (R03) funded by NIDCR. Any PD/PI who has already received funding for two NIDCR Small Grants for New Investigators (R03) is not eligible.
Investigators who have questions about eligibility should contact the Scientific/Research Contact listed in Section VII. Agency Contacts.

The Inspiring Generations of New Innovators to Impact Technologies in Energy (IGNIITE) program is designed to support a new cohort of early-career innovators to develop the most disruptive and unconventional ideas into transformative new technologies across the full spectrum of energy applications. This announcement is purposefully broad in technical scope, but eligibility is limited to early-career researchers as defined in Section III.A. In addition to research efforts, awardees will engage with ARPA-E and fellow awardees through dedicated IGNIITE events, meetings, and mentorship activities.

Submissions to this solicitation must propose transformational research and development (R&D) that have the potential for high impact. If successful, a project could create a new class or new trajectory for an energy technology, with the potential to substantially contribute to ARPA-E’s statutory goals (see Section I.A).

Awards under this program may take the form of exploratory research that provides the agency with information useful for the subsequent development of focused technology programs. Alternatively, awards may support proof-of-concept research for a particular new technology in an area not currently supported by the agency.

The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.

Eligible candidates will identify with one of the two categories below:

1. New Investigator (NI)

For the purpose of this NOFO, an investigator is considered a New Investigator (NI; https://grants.nih.gov/policy/early-investigators/index.htm) if they have not competed successfully for substantial, NIH independent funding from NIH. A "substantial" research award is a research grant award excluding smaller grants that maintain Early Stage Investigator (ESI)/NI status (see full list of awards here: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm). PD/PIs of NIH Training-Related and Mentored Career Awards are still considered New Investigators if the NIH awards are in any of the following categories: fellowships (F awards), individual or institutional career awards (K awards), and loan repayment contracts (L30, L32, L40, L50, L60). Appointees who have received support from any NIH training grants (T32, T34, T35, T90, D43) are also considered New Investigators.

OR

2. At-Risk Investigator

For the purpose of this NOFO, an investigator is considered an At-Risk Investigator if they have had prior support as a Principal Investigator on a substantial independent research award and, unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year. A "substantial" research award is a research grant award excluding smaller grants that maintain ESI/NI status

Research activities advance the NLN's goal of taking the "lead in the conduct of research that informs and promotes evidence-based teaching, advances the science of nursing education, and provides and interprets data about nursing education and the nurse educator workforce." Over the past decade, the NLN has provided funding of more than $1 million dollars for research in nursing education.

NLN Research in Nursing Education Grants (maximum grant up to $30,000)
Mary Anne Rizzolo Doctoral Research Award ($2,500 award for doctoral student)
Edmund J.Y. Pajarillo Health Informatics and Innovation Collaborative Research Award ($2,500 award for graduate student)

The purpose of the Agilent Early Career Professor Award is to:

Promote and encourage excellent research enabling measurements of importance to Agilent Technologies and the world
Establish strong collaborative relationships between Agilent researchers and leading professors early in their career
Build the prominence of Agilent as a sponsor of university research

Focus Topic: Contributions to environmental sustainability through development of green analytical technologies, methods, or laboratory working environments.

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
This Funding Opportunity Announcement does not accept applications proposing clinical trials.

The PhRMA Foundation Faculty Starter Grant in Drug Discovery Targets and Pathways offers financial support to individuals beginning independent careers in drug discovery research at the faculty level at an accredited U.S. university.

Successful drug discovery involves the innovative application and integration of multiple scientific disciplines to create efficacious, safe, and differentiated treatment options for patients. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease. 

Research topics could include, but are not limited to:  
Genomics and Proteomics 
Cellular and Molecular Biology 
Design and Generation of Pharmacological Tools  
In Vitro and/or In Vivo Pharmacology 
Protein Biochemistry 
Molecular Modelling 
Structural Biology 
Cell Imaging 
Single Cell Analysis 
Artificial Intelligence and Computational Approaches 
Projects that focus exclusively on single aspects such as identification of and development of assays for single targets, chemical probes, biomarkers, chemical library screening, or diagnostics will not be considered for review. Project aims should have a high likelihood of completion in the award timeframe.

Translational medicine is a scientific discipline focused on turning observations in the laboratory, clinic, and community into medicines, diagnostics, or other interventions that improve human health.

Translational medicine fosters a patient-focused research cycle that stretches from the lab bench to the patient bedside and back to the lab again. This includes adapting basic research discoveries in cells, tissues, and animals for application in humans and then taking the knowledge of what did and didn’t work in the clinic back to the bench.

Given the breadth of the discipline, the PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.

Applicants should work with clinical collaborators to identify unmet clinical needs. Proposals should integrate innovative technologies, with advanced biological, chemical, diagnostic, and pharmacological sciences and engineering methodologies in areas that include but not are limited to:
Genetics (Molecular, Pharmaco-, Population, Medical)
Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative)
Systems (Biology and Pharmacology)
Pathways and Networks
Integrative Biology
Modeling and Simulation
Target Identification and Validation
Biomarker Identification and Validation
Molecular Epidemiology
Imaging
Disease Modeling

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Components of Participating Organizations:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Human Genome Research Institute (NHGRI)